April 07, 2022
The well-known biotechnology holding company Kizoo has engaged in another funding round, this time for Elastrin Therapeutics, a company that focuses on returning stiff tissues to their natural state. The full press release is included here. Greenville, SC, U.S, April 7, 2022 – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to...
March 18, 2022
Revel Pharmaceuticals, a holding of Kizoo Technology Capital, has announced that it is seeking $8.4 million dollars in investment funding in order to develop its enzyme-based approach towards ending age-related diseases. The full press release is included below. Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing Based Approaches to Reversing Aging Led...
September 23, 2021
The investment company Kizoo has announced that one of the companies in its portfolio, Underdog Pharmaceuticals, has received $10 million in funding from a Series Seed II round. Mike Kope, who is well-known for his work in SENS Research Foundation, is the co-CEO of Underdog. As we have previously reported, this company is focused on...
May 06, 2021
It is always good to report on positive news for a change, and today is one of those happy occasions. Michael Greve, founder of Forever Healthy and Kizoo, has commited €300 million (just over $360 million at the time of writing) to support the development of rejuvenation biotechnology startups. More support flowing in for technology...
March 04, 2021
Rejuvenation biotechnology startup founder Kizoo has provided Elastrin, a company that focuses on removing calcification from tissue, with seed funding. The company Elastrin is named for elastin, which comprises the fibers affected by this calcification. The company is using a proprietary antibody to deliver a nanoparticle-encased therapeutic agent directly to the fibers in question. The...
January 08, 2020
Some pleasant news has recently arrived: Revel Pharmaceuticals has successfully completed a seed round in order to begin developing therapeutics that target glucosepane crosslinks, which are a proposed reason why we age, develop diseases such as diabetes, and suffer from stiffened arteries and hypertension. In the business of startups, a seed round refers to a...